Correction

Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

Emily Marden,¹ Ioanna Ntai,² Scott Bass,³ and Beat Flühmann^{2,4}

; published online 25 September 2018

Correction to: The AAPS Journal (2018) 20: 92

<https://doi.org/10.1208/s12248-018-0255-0>

In the published article the given name and the family name for each author is listed in the incorrect order and therefore cited incorrectly. The correct order (given name followed by family name) of names is listed above.

The online version of the original article can be found at <https://doi.org/10.1208/s12248-018-0255-0>

¹ Food, Drug and Medical Device Regulatory Law, Sidley Austin LLP, Palo Alto, California, USA.

² Non-Biological Complex Drugs, Vifor Pharma Ltd., Flughofstrasse 61, 8152, Opfikon, Switzerland.

³ Global Life Sciences, Sidley Austin LLP, Washington, D.C., USA.

⁴ To whom correspondence should be addressed. (e-mail: beat.fluehmann@viforpharma.com)